Outcomes in Patients with FLT3-Mutated Relapsed/ Refractory Acute Myelogenous Leukemia Who Underwent Transplantation in the Phase 3 ADMIRAL Trial of Gilteritinib versus Salvage Chemotherapy

Alexander E. Perl, Richard A. Larson, Nikolai A. Podoltsev, Stephen Strickland, Eunice S. Wang, Ehab Atallah, Gary J. Schiller, Giovanni Martinelli, Andreas Neubauer, Jorge Sierra, Pau Montesinos, Christian Recher, Sung Soo Yoon, Yoshinobu Maeda, Naoko Hosono, Masahiro Onozawa, Takayasu Kato, Hee Je Kim, Nahla Hasabou, Rishita NuthethiRamon Tiu, Mark J. Levis

Division of Hematology

University of Pennsylvania
The University of Chicago
Yale University
Vanderbilt University
Roswell Park Cancer Institute
Medical College of Wisconsin
University of California at Los Angeles
IRCCS Istituto scientifico romagnolo per lo studio e la cura dei tumori - Meldola (FC)
University of Marburg
Hospital de La Santa Creu I Sant Pau
Hospital Universitario La Fe
CHU de Toulouse
Seoul National University
Okayama University
University of Fukui
Hokkaido University
University of Tsukuba
Astellas Pharma Inc.
Johns Hopkins University

Research output: Contribution to journal › Article › peer-review

23 Scopus citations

Sort by
Weight
Alphabetically

Outcomes in Patients with FLT3-Mutated Relapsed/ Refractory Acute Myelogenous Leukemia Who Underwent Transplantation in the Phase 3 ADMIRAL Trial of Gilteritinib versus Salvage Chemotherapy

Fingerprint

Pharmacology, Toxicology and Pharmaceutical Science

Medicine and Dentistry

Immunology and Microbiology